Synchron Secures $200M to Commercialize Thought-Controlled Brain-Computer Interfaces

A $200 million injection into Synchron’s brain-computer interface technology could redefine medical care—or raise urgent ethical questions about neural innovation.

Synchron has raised $200 million to commercialize 'thought control' technology. The funding aims to accelerate development of brain-computer interface (BCI) devices. 'Thought control' refers to systems enabling users to control devices via neural signals.

The financial backing will support scaling of clinical trials, regulatory submissions, and manufacturing infrastructure for commercial deployment.

Brain-computer interface systems translate neural activity into actionable commands for external devices. Synchron’s approach focuses on non-invasive neural signal acquisition methods, distinguishing it from implant-based competitors.

The company has previously demonstrated prototype devices capable of translating motor cortex signals into cursor movements on screens.

⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.